Sunday, November 8, 2026

USD/JPY Bearish By 2% In The Last 21 Sessions

ViaNews Editorial Team

September 30, 2024

USD/JPY Bearish By 2% In The Last 21 Sessions

(VIANEWS) - USD/JPY (USDJPY) has been up by 2.26% for the last 21 sessions. At 17:08 EST on Monday, 30 September, USD/JPY (USDJPY) is $143.60.

Usd/jpy struggles to capitalize on modest intraday gains, up a little around mid-142.00s

The USD/JPY pair attracts some dip-buyers at the start of a new week and reverses a part of Friday's sharp retracement slide from the 146.50 area or over a three-week high. , This, along with news that the new PMI is planning a general election for October 27 and mixed Japanese economic data, undermines the Japanese Yen (JPY) and is seen lending support to the USD/JPY pair.

Usd/jpy: bullish momentum on daily chart fades – OCBC

The risk she may win was one of the factors that kept USD/JPY rather supported for most of last week. , Last Friday, USD/JPY traded up to high of 146.49 after candidate Takaichi managed to get into run-off against Ishiba.

USD/JPY's yearly highs and lows, it's 2.884% up from its 52-week low and 11.324% down from its 52-week high.

Volatility

USD/JPY's last week, last month's, and last quarter's current intraday variation average was a negative 0.19%, a negative 0.09%, and a positive 0.59%, respectively.

USD/JPY's highest amplitude of average volatility was 0.75% (last week), 0.59% (last month), and 0.59% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/JPY's Forex is considered to be overbought (>=80).

More news about USD/JPY (USDJPY).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com